看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Current progress in innovative engi... 收藏
Current progress in innovative engineerec antibodies

Current progress in innovative engineerec antibodies

作     者:William R. Strohl 

作者机构:BiStro Biotech Consulting Bridgewater NJ 08807 USA 

基  金:Centers for Disease Control and Prevention, CDC Johnson and Johnson, J&J 

出 版 物:《Protein & Cell》 (蛋白质与细胞(英文版))

年 卷 期:2018年第9卷第1期

页      码:86-120页

摘      要:As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody- based molecules in phase III and phase 1/11 clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibody- drug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are being discovered each year. For oncol- ogy, many of the exciting new approaches involve anti- body modulation of T-cells. There are over 80 antibodies in clinical trials targeting T cell checkpoints, 26 T-cell- redirected bispecific antibodies, and 145 chimeric anti- gen receptor (CAR) cell-based candidates (all currently in phase I or II clinical trials), totaling more than 250 T cell interacting clinical stage antibody-based candi- dates. Finally, significant progress has been made recently on routes of delivery, including delivery of proteins across the blood-brain barrier, oral delivery to the gut, delivery to the cellular cytosol, and gene- and viral-based delivery of antibodies. Thus, there are cur- rently at least 864 antibody-based clinical stage mole- cules or cells, with incredible diversity in how they are constructed and what activities they impart. These are followed by a next wave of novel molecules, approa- ches, and new methods and routes of delivery, demon- strating that the field of antibody-based biologics is very innovative and diverse in its approaches to fulfill their promise to treat unmet medical needs.

主 题 词:antibody clinical candidates engineered antibodies chimeric antigen receptors 

学科分类:0710[理学-生物科学类] 071010[071010] 081704[081704] 07[理学] 08[工学] 0817[工学-轻工类] 081201[081201] 0812[工学-测绘类] 

核心收录:

D O I:10.1007/s13238-017-0457-8

馆 藏 号:203284434...

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分